Adenosyl-Ornithine;A-9145;Antibiotic 32232RP

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: Adenosyl-Ornithine;A-9145;Antibiotic 32232RP
• 英文别名: 2,5-diamino-6-[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]hexanoic acid
• 化学式: C₁₅H₂₃N₇O₅
• 分子量: 381.39
• InChiKey: LMXOHSDXUQEUSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.3
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  209
• 氢给体数：
  6
• 氢受体数：
  11

文献信息

• Inhibitors of DNA Methyltransferase
  申请人：Wahhab Amal

  公开号：US20080132525A1

  公开（公告）日：2008-06-05

  The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.

  这项发明涉及抑制DNA甲基转移酶亚型DNMT1和DNMT3b2。该发明提供了用于抑制DNMT1和DNMT3b2的化合物和方法。
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF RNA VIRAL INFECTIONS<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT D'INFECTIONS VIRALES À ARN
  申请人：UNIV CALIFORNIA

  公开号：WO2018075947A1

  公开（公告）日：2018-04-26

  Disclosed herein, inter alia, are agents having antiviral activity and methods of use thereof.

  本公开的内容包括具有抗病毒活性的药物和使用方法。
• EPIGENETIC REGULATORS OF FRATAXIN
  申请人：RANA THERAPEUTICS, INC.

  公开号：US20160201063A1

  公开（公告）日：2016-07-14

  Provided herein are methods for increasing Frataxin (FXN) expression that involve targeting or expressing regulatory factors that modulate the epigenetic state of FXN genes. Also provided herein are methods for increasing FXN expression using inhibitors of a negative epigenetic regulator of FXN. Compositions and methods for treating Friedrich's ataxia are also provided.
• COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
  申请人：MOUNIR Zineb

  公开号：US20170283807A1

  公开（公告）日：2017-10-05

  The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating subjects having TMPRSS2:ERG positive prostate cancer, which we show is amenable to therapeutic treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment are also provided.
• INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES
  申请人：NOVARTIS AG

  公开号：US20180010132A1

  公开（公告）日：2018-01-11

  The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is MTAP-deficient and/or MTA-accumulating and thus amenable to therapeutic treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment are also provided.